Clinical Pharmacokinetics

, Volume 23, Issue 6, pp 415–427 | Cite as

Clinical Pharmacokinetics of Ketorolac Tromethamine

  • Dion R. Brocks
  • Fakhreddin Jamali
Review Article Drug Disposition

Summary

Ketorolac is a new chiral nonsteroidal anti-inflammatory drug (NSAID) which is marketed for analgesia as the racemate. The drug is administered as the water soluble tromethamine salt and is available in tablets or as an intramuscular injection. The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min. Its oral bioavailability is estimated to range from 80 to 100%. The drug is extensively bound (>99%) to plasma proteins and has a volume of distribution (0.1 to 0.3 L/kg) comparable with those of other NSAIDs. Only small concentrations of ketorolac are detectable in umbilical vein blood after administration to women in labour. The elimination half-life is between 4 and 6h and is moderate in comparison with other NSAIDs. The area under the plasma concentration-time curve of ketorolac is proportional to the dose after intramuscular administration of therapeutic doses to young healthy volunteers.

Ketorolac is extensively metabolised through glucuronidation and oxidation; little if any drug is eliminated unchanged. Most of the dose of ketorolac is recovered in the urine as conjugated drug. Although ketorolac is excreted into the breast milk, the amount of drug transferred comprises only a small fraction of the maternal exposure. Little stereoselectivity was present in the pharmacokinetics of ketorolac in a healthy volunteer receiving single intravenous or oral doses. The elderly exhibit reduced clearance of the drug. Renal insufficiency appears to cause an accumulation of ketorolac in plasma, although hepatic disease may not affect the pharmacokinetics.

Keywords

Warfarin Ketoprofen Ketorolac Clinical Pharmacokinetic Plasma Protein Binding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahn HY, Jamali F, Cox SR, Kittayanond D, Smith DE. Stereoselective disposition of ibuprofen enantiomers in the isolated perfused rat kidney. Pharmaceutical Research 8: 1520–1524, 1991PubMedCrossRefGoogle Scholar
  2. Anonymous. Toradol prescribing information. Syntex Inc. and Upjohn Co. of Canada. 1991Google Scholar
  3. Brocks DR, Jamali F, Russell AS. Stereoselective disposition of etodolac enantiomers in synovial fluid. Journal of Clinical Pharmacology 31: 741–746, 1991PubMedGoogle Scholar
  4. Buckley MMT, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 39: 86–109, 1990PubMedCrossRefGoogle Scholar
  5. D’Arienzo M, Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs in Experimental Clinical Research 10: 863–866, 1984Google Scholar
  6. Debruyne D, de Ligny H, Ryckelynck J, Albessard F, Moulin M. Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. Clinical Pharmacokinetics 12: 214–221, 1987PubMedCrossRefGoogle Scholar
  7. Bach AJ, Lavelle CJ, Olander KW, Retzlaff JA, Sorenson LW. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 95: 1279–1284, 1988Google Scholar
  8. Forbes JA, Butterworth GA, Burchfield WH, Beaver AT. Evaluation of ketorolac, aspirin, and acetaminophen-codeine combination in postoperative oral surgery pain. Pharmacotherapy 10: 77S–93S, 1990PubMedGoogle Scholar
  9. Guzman A, Yuste F, Toscano RA, Young JM, Van Horn AR. Absolute configuration of (−)-5-benzoyl-1,2-dihydro-3H-pyr-rolo[1,2-a]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac. Journal of Medicinal Chemistry 29: 589–591, 1986PubMedCrossRefGoogle Scholar
  10. Jallad NS, Garg DC, Martinez JJ, Mroszczak EJ, Weidler DJ. Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. Journal of Clinical Pharmacology 30: 76–81, 1990PubMedGoogle Scholar
  11. Jamali F, Stevens DRS. Naproxen excretion in milk and its uptake by the infant. Drug Intelligence and Clinical Pharmacy 17: 910–911, 1983PubMedGoogle Scholar
  12. Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. European Journal of Drug Metabolism and Pharmacokinetics 13: 1–9, 1988PubMedCrossRefGoogle Scholar
  13. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. Journal of Pharmaceutical Sciences 78: 695–715, 1989aPubMedCrossRefGoogle Scholar
  14. Jamali F, Pasutto FM, Lemko C. HPLC of ketorolac enantiomers and application to pharmacokinetics in the rat. Journal of Liquid Chromatography 12: 1835–1850, 1989bGoogle Scholar
  15. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clinical Pharmacokinetics 19: 197–217, 1990PubMedCrossRefGoogle Scholar
  16. Jung D, Mroszczak EJ, Bynum L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular, and oral administration. European Journal of Clinical Pharmacology 35: 423–425, 1988PubMedCrossRefGoogle Scholar
  17. Jung D, Mroszczak EJ, Wu AT, Ling TL, Sevelius H, et al. Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. Pharmaceutical Research 6: 62–65, 1989PubMedCrossRefGoogle Scholar
  18. Kanto J. Obstetric analgesia: clinical pharmacokinetic considerations. Clinical Pharmacokinetics 11: 283–298, 1986PubMedCrossRefGoogle Scholar
  19. Kohler G, Primbs P, Morand J, Rubelt CH. Correlation between ketoprofen plasma levels and analgesic effect in acute lumbar pain and radicular pain. Clinical Rheumatology 4: 399–404, 1985PubMedCrossRefGoogle Scholar
  20. Laska EM, Sunshine A, Marrero I, Olson N, Siegel C, et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clinical Pharmacology and Therapeutics 40: 1–7, 1986PubMedCrossRefGoogle Scholar
  21. Levy G. Decreased body clearance of diflunisal in renal insufficiency — an alternate explanation. British Journal of Clinical Pharmacology 8: 601, 1979PubMedCrossRefGoogle Scholar
  22. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics 12: 402–432, 1987PubMedCrossRefGoogle Scholar
  23. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. Journal of Pharmaceutical Sciences 76: 289–294, 1987PubMedCrossRefGoogle Scholar
  24. Litvak KM, McEvoy GK. Ketorolac, an injectable non-narcotic analgesic. Clinical Pharmacy 9: 921–935, 1990PubMedGoogle Scholar
  25. Martinez J, Garg DC, Pages LJ, Jallad NS, Yee JP, et al. Single dose pharmacokinetics of ketorolac in healthy young and renal impaired subjects. Abstract No. 72. Journal of Clinical Pharmacology 27: 722, 1987Google Scholar
  26. Mroszczak EJ, Ling T, Yee J, Massey I, Sevelius H. Ketorolac tromethamine absorption and pharmacokinetics in humans. Clinical Pharmacology and Therapeutics 37: 215, 1985Google Scholar
  27. Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang B, et al. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metabolism and Disposition 15: 618–626, 1987PubMedGoogle Scholar
  28. Mroszczak EJ, Jung D, Yee J, Bynum L, Sevelius H, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy 10: 33S–39S, 1990PubMedGoogle Scholar
  29. Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clinical Pharmacokinetics 17: 145–162, 1989PubMedCrossRefGoogle Scholar
  30. Notarianni LJ, Oldham HG, Bennett PN. Passage of paracetamol into breast milk and its subsequent metabolism by the neonate. British Journal of Clinical Pharmacology 24: 63–67, 1987PubMedCrossRefGoogle Scholar
  31. Olkkola KT, Maunuksela E. The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children. British Journal of Clinical Pharmacology 31: 182–184, 1991PubMedCrossRefGoogle Scholar
  32. Pages LJ, Martinez JJ, Garg DC, Yee JP, Mroszczak J, et al. Pharmacokinetics of ketorolac tromethamine in hepatically impaired vs young healthy subjects. Abstract No. 78. Journal of Clinical Pharmacology 27: 724, 1987Google Scholar
  33. Resman-Targof TBH. Ketorolac: a parenteral nonsteroidal antiinflammatory drug. Drug Intelligence and Clinical Pharmacy 24: 1098–1104, 1990Google Scholar
  34. Reynolds J. (Ed.) Analgesic and antiinflammatory drugs. In: Martindale the extra pharmacopoeia, 29th ed., pp. 1–46, Pharmaceutical Press, London, 1989Google Scholar
  35. Rooks WH II, Tomolonis AJ, Maloney PJ, Wallach MB, Schuler ME. The analgesic and anti-inflammatory profile of (+)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619). Agents and Actions 12: 684–690, 1982PubMedCrossRefGoogle Scholar
  36. Rooks WH II, Maloney PJ, Shott PJ, Schuler ME, Sevelius H, et al. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs in Experimental Clinical Research 11: 479–492, 1985Google Scholar
  37. Rooks WH. The pharmacologic activity of ketorolac tromethamine. Pharmacotherapy 10 (Suppl.): 30S–32S, 1990PubMedGoogle Scholar
  38. Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E. Nonlinear plasma level response to high doses of naproxen. Clinical Pharmacology and Therapeutics 15: 261–266, 1974PubMedGoogle Scholar
  39. Singh NN, Jamali F, Pasutto FM, Russell AS, Coutts RT, et al. Pharmacokinetics of the enantiomers of tiaprofenic acid in humans. Journal of Pharmaceutical Sciences 75: 439–442, 1986PubMedCrossRefGoogle Scholar
  40. Stanski DR, Cherry C, Bradley R, Sarnquist FH, Yee JP. Efficacy and safety of single doses of intramuscular ketorolac tromethamine compared with meperidine for postoperative pain. Pharmacotherapy 10 (Suppl.): 40S–44S, 1990PubMedGoogle Scholar
  41. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35: 244–285, 1988PubMedCrossRefGoogle Scholar
  42. Toon S, Holt BL, Mullins GP, Bullingham R, Aarons L, et al. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. British Journal of Clinical Pharmacology 30: 743–750, 1990PubMedCrossRefGoogle Scholar
  43. Townsend RJ, Benedetti TJ, Erickson SH, Cengiz C, Gillespie WR, et al. Excretion of ibuprofen into breast milk. American Journal of Obstetrics and Gynaecology 149: 184–186, 1984Google Scholar
  44. Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. Journal of Pharmaceutical Sciences 69: 1254–1257, 1980PubMedCrossRefGoogle Scholar
  45. Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics 8: 297–331, 1983PubMedCrossRefGoogle Scholar
  46. Verbeeck RK, Wallace SM, Loewen GR. Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation. British Journal of Clinical Pharmacology 17: 783–784, 1984PubMedCrossRefGoogle Scholar
  47. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical Pharmacokinetics 19: 44–66, 1990PubMedCrossRefGoogle Scholar
  48. Walker JJ, Johnstone J, Lloyd J, Rocha CL. The transfer of ketorolac tromethamine from maternal to foetal blood. European Journal of Clinical Pharmacology 34: 509–511, 1988PubMedCrossRefGoogle Scholar
  49. Wilson SJ, Errick JK, Balkon J. Pharmacokinetics of nalbuphine during parturition. American Journal of Obstetrics and Gynaecology 155: 340–344, 1986Google Scholar
  50. Wischnik A, Manth SM, Lloyd J, Bullingham R, Thompson JS. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. European Journal of Clinical Pharmacology 36: 521–524, 1989PubMedCrossRefGoogle Scholar
  51. Wu AT, Huang BL, Massey IJ, Kushinsky S. Quantification of ketorolac in plasma and aqueous humor by high performance liquid chromatography. American Pharmaceutical Association Abstracts 16: 145, 1986Google Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Dion R. Brocks
    • 1
  • Fakhreddin Jamali
    • 1
  1. 1.Faculty of Pharmacy and Pharmaceutical SciencesUniversity of AlbertaEdmontonCanada

Personalised recommendations